Limited time offer! 10% off your first blood test order!
Seven-marker fertility panel — AMH, FSH, LH, oestradiol, progesterone, prolactin, and TSH — for comprehensive female reproductive assessment.
or 4 interest-free payments of £32.25 with Klarna
A seven-marker female fertility panel covering AMH, FSH, LH, oestradiol, progesterone, prolactin, and TSH.
Fertility is influenced by a complex interplay of hormones across the pituitary, ovaries, thyroid, and elsewhere. The Female Fertility Hormone Panel measures seven key markers that together provide a comprehensive overview of female reproductive hormonal health.
AMH (anti-Mullerian hormone) is the most reliable marker of remaining ovarian reserve — the number of eggs left. FSH and LH on day 2 to 5 of the cycle reflect pituitary drive and the quality of the ovarian response. Oestradiol at baseline contextualises the FSH value. Progesterone on day 21 confirms whether ovulation occurred and the quality of the luteal phase. Prolactin screens for hyperprolactinaemia — a frequently missed cause of anovulation and infertility. TSH screens for thyroid dysfunction, which directly affects fertility and pregnancy outcome.
This panel requires careful cycle-day timing. Ideally, FSH, LH, oestradiol, and prolactin are collected on days 2 to 5; progesterone on day 21. If confirming ovulation only, a day 21 progesterone alone is sufficient. Venous draw required. GMC-physician reviewed results within 5 to 7 working days.
Understand what each marker measures, why it matters, and what the science says — not just a list of numbers.
Produced by growing follicles; reflects remaining egg pool independent of cycle day — the best single marker of ovarian reserve.
Measured on days 2 to 5; elevated FSH signals declining ovarian reserve or reduced ovarian response.
Measured on days 2 to 5; LH-to-FSH ratio supports or challenges PCOS as a diagnosis.
Baseline oestradiol on days 2 to 5 contextualises FSH; elevated early oestradiol can suppress FSH and give a falsely reassuring reading.
Day 21 measurement confirms ovulation occurred; a level above 30 nmol/L indicates adequate luteal phase quality.
Pituitary hormone that causes anovulation and irregular cycles when elevated; a common, treatable cause of fertility disruption.
Thyroid dysfunction is a leading cause of anovulation and pregnancy loss; TSH screening is essential in any fertility investigation.
This panel is designed for adults who want a comprehensive, evidence-based picture of their metabolic health — not a GP referral panel.
Women who have been trying to conceive for 6 or more months without success
Those with irregular or absent periods wanting to investigate ovulation
Women planning pregnancy in the next 1 to 2 years wanting to understand their fertility window
Those who have experienced one or more pregnancy losses
AMH reflects ovarian reserve (egg quantity) but cannot predict egg quality, which is the most important determinant of conception success in women over 35. A normal AMH does not guarantee conception; a low AMH does not preclude it. FSH must be collected on days 2 to 5 for clinical relevance; a high FSH on any other cycle day may not be meaningful. Progesterone should be collected approximately 7 days after ovulation (not necessarily day 21 in women with irregular cycles). This panel does not include assessment of the uterus, fallopian tubes, or male partner fertility. Please share results with your GP or fertility specialist rather than adjusting treatment independently based on these findings.
From order to physician-reviewed report in as little as three working days.
Three options designed to fit your schedule, location, and preference — all producing a laboratory-standard sample.
Adults 18+ in mainland UK. Not suitable if you have had a transfusion in the last 3 months.
Order anytime; kit dispatched within 24 hours Mon–Fri.
Allow 24–48 hours for sample transit on top of lab processing time.
Adults 18+ within 20 miles of a serviced city centre.
Mon–Sun, 06:00–20:00. Next-day booking typical.
Sample reaches the lab within 24 hours of collection.
Adults 16+ with photo ID. Paediatric draws by appointment at selected sites.
Mon–Fri, with Saturday hours at most metropolitan locations.
Samples processed same-day at the receiving clinic.
Every test is processed in a UKAS ISO 15189-accredited laboratory, overseen by GMC-registered physicians, and governed by UK GDPR. No overseas processing, no offshore data.
Follow these guidelines to ensure accurate, reproducible results. Most markers are sensitive to recent food, exercise, and sleep.
Can't find your answer? Our clinical support team is available Monday to Friday, 9am–5pm.
Contact supportAMH (anti-Mullerian hormone) is produced by the granulosa cells of small growing follicles in the ovaries and reflects the size of the remaining follicle pool — the ovarian reserve. A higher AMH indicates more eggs remaining; lower AMH indicates a smaller reserve. AMH is the most reliable single marker of ovarian reserve available from a blood test and can be measured at any point in the cycle without significant day-to-day variation. However, AMH tells you about egg quantity, not quality — which becomes the more critical determinant of natural conception after 35. Low AMH does not mean you cannot conceive naturally; it means time may be more limited.
AMH levels decline naturally with age. Very broadly, AMH above 15 pmol/L in a woman under 35 is considered reassuring. Values between 5 and 15 pmol/L are in a typical working range. Values below 5 pmol/L indicate reduced ovarian reserve, and below 2 pmol/L suggests very low reserve. However, these thresholds vary between laboratories and should be interpreted against age-adjusted reference intervals. Even with very low AMH, natural conception can and does occur — AMH predicts the number of eggs available, not whether one will fertilise and implant successfully. Your physician report will interpret your AMH in the context of your age and clinical picture.
FSH (follicle-stimulating hormone) fluctuates significantly throughout the menstrual cycle. During the early follicular phase (days 2 to 5), FSH is at its ‘baseline’ level — reflecting how hard the pituitary is working to stimulate follicle development. If the ovaries are less responsive (as in declining ovarian reserve or early menopause), the pituitary releases more FSH to compensate. This elevated baseline FSH is the key signal. Measuring FSH later in the cycle — around ovulation or in the luteal phase — gives very different values that are not clinically interpretable as an ovarian reserve indicator.
In a standard 28-day cycle, ovulation typically occurs around day 14 and progesterone peaks approximately 7 days later — hence ‘day 21 testing’. A progesterone level above 30 nmol/L on day 21 confirms ovulation occurred and indicates an adequate luteal phase. A value below this suggests either anovulation (no ovulation occurred) or inadequate luteal phase support, both of which can impair implantation. In women with irregular cycles, a day 21 test may not capture the progesterone peak — ovulation predictor kits can identify ovulation timing, and testing 7 days after a confirmed ovulation gives a more reliable result.
Elevated prolactin (hyperprolactinaemia) suppresses gonadotrophin-releasing hormone (GnRH) from the hypothalamus, reducing LH and FSH release from the pituitary. Lower LH and FSH mean reduced or absent ovulation, leading to irregular or absent periods and infertility. Prolactin can be elevated by pituitary adenomas (prolactinomas), certain medications (antipsychotics, antiemetics), hypothyroidism, and physiological stress including the blood draw itself. When a prolactinoma is identified, treatment with cabergoline (a dopamine agonist) normalises prolactin within weeks to months, restoring ovulation and dramatically improving fertility — without surgery in most cases.
Thyroid dysfunction — both overactive and underactive — directly impairs fertility. Hypothyroidism reduces ovulation frequency and can cause irregular or absent periods. Even subclinical hypothyroidism (mildly elevated TSH with normal FT4) is associated with reduced conception rates and increased miscarriage risk. Untreated hypothyroidism is also associated with impaired fetal neurodevelopment in early pregnancy. TSH screening before or during conception attempts is recommended by NICE and international fertility guidelines; optimal TSH for conception is considered to be below 2.5 mIU/L in most guidelines, though this threshold is debated.
The NHS recommends a GP referral to a fertility specialist after 12 months of unprotected regular intercourse without conception in women under 35, and after 6 months in women 35 and over. You do not need to wait for these timeframes to obtain private testing — early assessment of hormonal status can identify treatable causes (thyroid dysfunction, elevated prolactin, PCOS, poor ovarian reserve) that, if addressed early, significantly improve the chance of natural conception. If your Trupoint Health results identify concerning findings, the physician report will advise on the appropriate speed and route for specialist referral.
